Skip to content

Prevention and treatment of postpartum depression in cesarean delivery women with esketamine

Prevention and treatment of postpartum depression in cesarean delivery women with esketamine

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200064860
Enrollment
Unknown
Registered
2022-10-20
Start date
2022-04-25
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum Depression

Interventions

Group A:5 minutes after delivery, the fetus was given intravenous esticketamine 0.125mg/kg. Postoperative intravenous analgesia pump: butorphenol 0.125mg/kg+ ondansetron 8mg plus normal saline was con
Group B:Esticketamine 0.125mg/kg was given intravenously 5 minutes after delivery. Postoperative analgesia pump: esticketamine 1mg/kg+ Butorphenol 0.125mg/kg+ ondansetron 8mg plus normal saline was co
Group C:5 minutes after delivery, the fetus was given 0.25mg/kg esticketamine intravenously. Postoperative intravenous analgesia pump: butorphenol 0.125mg/kg+ ondansetron 8mg plus normal saline was co
Group D:5 minutes after delivery, the fetus was given 0.25mg/kg esticketamine intravenously. Postoperative analgesia pump: esticketamine 1mg/kg+ butorphanol 0.125mg/kg+ ondansetron 8mg plus normal sal
Group E:Esketamine is not used. Postoperative intravenous analgesic pump: Butorphanol 0.125mg/kg+ ondansetron 8mg + normal saline was configured to 100mL

Sponsors

Xi 'an International Medical Center Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Aged 20-50 years; 2. ASA I-II; 3. Gestation > 28 weeks: 4. Postoperative analgesia treatment is required; 5. Cesarean section in our hospital; 6. Agree to participate in the study and sign the agreement.

Exclusion criteria

Exclusion criteria: 1. Patients with serious cardiovascular and cerebrovascular diseases, serious liver and kidney dysfunction and other important organ failure; 2. Allergic to opioids, sedative-hypnotic drugs, or psychotropic drugs or a history of such drugs abuse: 3. Communication disorders or mental disorders; 4. The investigator considers it unsuitable for this clinical investigator.

Design outcomes

Primary

MeasureTime frame
Edinburgh Postnatal Depression Scale;

Secondary

MeasureTime frame
Pittsburgh Sleep Quality Index, PSQI;Vital signs;Numeric Rating Scale (NRS) for pain ;PCA frequency of postoperative analgesia pump;

Countries

China

Contacts

Public ContactWang Binrong

Xi 'an International Medical Center Hospital

549676914@qq.com+86 13659289992

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026